Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

  • Alonso-García, Miriam
  • Sánchez-Gastaldo, Amparo
  • Muñoz-Fuentes, Miguel A.
  • Molina-Pinelo, Sonia
  • Boyero, Laura
  • Benedetti, Johanna
  • Bernabé Caro, Reyes
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55−1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52−1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab., RBC was funded by the Andalusian Research, Development and Innovation Plan (PY20_00951) and co-financed by the European Regional Development Fund (ERDF). SMP was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (PI-0046-2012, Nicolas Monardes Program RC-0004-2020, OH-0022-2018 and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992), and ISCIII (PI17/00033 and PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union). LB was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (RH-0051-2020). JCB was funded by ISCIII (CM20/00178) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

  • Marrugal, Ángela
  • Ferrer, Irene
  • Quintanal-Villalonga, Álvaro
  • Ojeda, Laura
  • Pastor, María Dolores
  • García-Luján, Ricardo
  • Carnero, Amancio
  • Paz-Ares, Luis
  • Molina-Pinelo, Sonia
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The use of 90 kDa heat shock protein (HSP90) inhibition as a therapy in lung adenocarcinoma remains limited due to moderate drug efficacy, the emergence of drug resistance, and early tumor recurrence. The main objective of this research is to maximize treatment efficacy in lung adenocarcinoma by identifying key proteins underlying HSP90 inhibition according to molecular background, and to search for potential biomarkers of response to this therapeutic strategy. Inhibition of the HSP90 chaperone was evaluated in different lung adenocarcinoma cell lines representing the most relevant molecular alterations (EGFR mutations, KRAS mutations, or EML4-ALK translocation) and wild-type genes found in each tumor subtype. The proteomic technique iTRAQ was used to identify proteomic profiles and determine which biological pathways are involved in the response to HSP90 inhibition in lung adenocarcinoma. We corroborated the greater efficacy of HSP90 inhibition in EGFR mutated or EML4-ALK translocated cell lines. We identified proteins specifically and significantly deregulated after HSP90 inhibition for each molecular alteration. Two proteins, ADI1 and RRP1, showed independently deregulated molecular patterns. Functional annotation of the altered proteins suggested that apoptosis was the only pathway affected by HSP90 inhibition across all molecular subgroups. The expression of ADI1 and RRP1 could be used to monitor the correct inhibition of HSP90 in lung adenocarcinoma. In addition, proteins such as ASS1, ITCH, or UBE2L3 involved in pathways related to the inhibition of a particular molecular background could be used as potential response biomarkers, thereby improving the efficacy of this therapeutic approach to combat lung adenocarcinoma., I.F. was funded by i + 12 and ISCIII (PI19/00320, CP21/0052) and co-funded by FEDER from Regional Development European Funds (European Union). L.P-A. was funded by the Comunidad de Madrid, CAM, (B2017/BMD3884), AECC (TRNSC18004PAZ), Fundación CRIS contra el cancer (Unidad Integral CRIS de Inmuno-oncología, 2018/0043), ISCIII (PI20/00870; AC20/0070) and CIBERONC (CD16/12/00442), and co-funded by FEDER from Regional Development European Funds (European Union). S.M-P. was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (Nicolás Monardes Program RC-0004-2020 and PECART-0091-2020), and Andalusian Research, Development and Innovation Plan (PY20_00992), ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Small cell lung cancer unveiled: Exploring the untapped resource of circulating tumor cells-derived organoids

  • Pérez-Cabello, Jesús Ángel
  • Artero-Castro, Ana
  • Molina-Pinelo, Sonia
Small cell lung cancer (SCLC) remains a challenge in oncology due to its aggressive behavior and dismal prognosis. Despite advances in treatments, novel strategies are urgently needed. Enter liquid biopsy-a game-changer in SCLC management. This revolutionary non-invasive approach allows for the analysis of circulating tumor cells (CTCs), offering insights into tumor behavior and treatment responses. Our review focuses on a groundbreaking frontier: harnessing CTCs to create three-dimensional (3D) organoid models. These models, derived from CTCs that break away from the primary tumor or metastatic locations, hold immense potential for revolutionizing cancer research, especially in SCLC. We explore the essential conditions for successfully establishing CTC-derived organoids-a transformative approach with profound implications for personalized medicine. Our evaluation spans diverse isolation techniques, shedding light on their advantages and limitations. Furthermore, we uncover the critical factors governing the cultivation of 3D organoids from CTCs, meticulously mimicking the tumor microenvironment. This review comprehensively elucidates the molecular characterization of these organoids, showcasing their potential in identifying treatment targets and predicting responses. In essence, our review amalgamates cutting-edge methodologies for isolating CTCs, establishing transformative CTC-derived organoids, and characterizing their molecular landscape. This represents a promising frontier for advancing personalized medicine in the complex realm of SCLC management and holds significant implications for translational research., The authors acknowledge funding from the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004–2020, and PECART-0091–2020), and Instituto de Salud Carlos III (ISCIII) through the projects PI20/01109, and PI23/01679 and co-funded by European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

  • Cirauqui, Cristina
  • Ojeda, Laura
  • Otano, Itziar
  • Pazos, Irene
  • Santos, Alba
  • Garrido-Martin, Eva M.
  • Yagüe, Patricia
  • Ramos-Paradas, Javier
  • Molina-Pinelo, Sonia
  • Roncador, Giovanna
  • Solórzano, José Luis
  • Muñoz Jiménez, María Teresa
  • Cozar, Patricia
  • Plaza, Patricia
  • Suárez, Rocío
  • Jiménez, Marta
  • Moreno, Roberto
  • Rosado, Arantxa
  • Gámez, Pablo
  • García-Luján, Ricardo
  • Zugazagoitia, Jon
  • Sweet-Cordero, Alejandro
  • Barbacid, Mariano
  • Carnero, Amancio
  • Ferrer, Irene
  • Paz-Ares, Luis
Cristina Cirauqui, Laura Ojeda, Irene Ferrer and Luis Paz-Ares contributed equally to this work., [Rationale] Interleukin-11 (IL-11) has emerged as a significant player in tumourigenesis, with implications across various cancer types. However, its specific role in driving tumour progression in lung adenocarcinoma (LUAD) remains elusive. IL-11's multifaceted impact on both tumour cells and the tumour microenvironment underscores its potential as a therapeutic target in LUAD. This study aims to unravel the involvement of IL-11 in LUAD progression and its influence on the tumour microenvironment., [Methods] Here, we used transcriptomic and digital spatial profiling analyses together with clinic data from two retrospective LUAD patient cohorts. LUAD cell lines genetically engineered to overexpress or to silence IL-11 or its receptor (IL-11RA) were used for in vitro functional analysis and for in vivo experiments. Additionally, we used three different in vivo models: patient-derived xenografts (PDXs), tobacco-exposed mice and genetically engineered mouse models. A neutralising monoclonal antibody against IL-11RA was produced and tested., [Results] Our findings revealed a pivotal role for IL-11 in driving tumourigenesis across various mouse models, highlighting its capacity to modulate tumour immunity towards an immunosuppressive microenvironment. Moreover, we observed a correlation between IL-11 expression and poorer patient outcomes in LUAD. Notably, therapeutic targeting of IL-11RA with a neutralising antibody demonstrated significant anti-tumour efficacy in a PDX model., [Conclusion] The IL-11/IL-11RA axis emerges as a critical driver of LUAD tumourigenesis, exerting its effects through enhanced tumour cell proliferation and remodelling of the tumour microenvironment. Our study highlights the therapeutic potential of disrupting this axis, suggesting that patients exhibiting elevated IL-11 levels may benefit from therapies targeting the IL-11/IL-11RA pathway., We would like to acknowledge patients and their families for donating tumour tissue. We would also like to thank Alicia Maroto Pérez and Carolina Castilla, as well as the Biobank of the Hospital 12 de Octubre and Hospital Virgen del Rocío for kindly providing the samples used in this study. Appreciation is also expressed to Ines Muñoz and Jorge L. Martinez-Torrecuadrada (CNIO) for producing the recombinant human IL-11 and IL-11RA. L.P.-A. was funded by CAM, (B2017/BMD3884, P2022/BMD-7437), Fundación CRIS contra el cancer, CIBERONC (CD16/12/00442) and ISCIII (PI17/00778; PI20/00870; AC20/0070) and I.F. by AECC (AIO2015) and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER (European Union). L.O. is funded by the Spanish Ministry of Education (FPU13/02595) and C.C. by ISCIII (CD21/00165). AC was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU), Plan Estatal de I+D+I 2021, Agencia Estatal de Investigación (AEI), Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): ID2021-122629OB-I00 and CIBER de Cáncer (CB16/12/00275). EASC was funded by U01CA199216 from the National Cancer Institute. S.M.-P. was funded by the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020, and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992) and ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed